Brought to you by 
Innate grosses €20.3mm through private placement to US investors
22 Nov 2013
Executive Summary
Innate Pharma SA (immunotherapies for cancer and inflammatory diseases) grossed €20.3mm ($27.3mm) through the sale of 7.6mm ordinary shares at €2.67 apiece (a 6% premium). The financing was subscribed entirely by US investors, including OrbiMed (which took a stake in Innate of over 5%), and funds managed by QVT Financial and Redmile Group.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Innate grosses €20.3mm through private placement to US investors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice